Singapore- Paradigm is pleased to announce the publication of an article titled "Performance of next-generation sequencing (NGS) on small tumor specimens and/or low tumor content samples" through PLOS ONE.

"About 1 in 5 patients seeking NGS are rejected due to small specimen size or too few tumor cells. We have reduced that number to 1 in 16 by accepting small fine needle aspirates and tissues with as little as 4% tumor cells," said Scott Morris, PhD, Chief Scientific Officer.   "This paper proves what physicians have been telling us: Paradigm is a great option when results are needed for immediate treatment decisions and there is not enough tissue or time to risk sample rejection."

The Paradigm Cancer Diagnostic (PCDx) testing is certified under the Clinical Laboratory Improvement Amendments (CLIA) and Paradigm has also been awarded accreditation by the College of American Pathologists (CAP).